Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, idolent or aggressive lymphoma
European Journal of Cancer(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
European Journal of Cancer(2015)